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Abstract  
Pancreatitis-associated protein 1 (PAP1) belongs to the Reg family of secretory proteins. 
Several important biological roles have been attributed to PAP1 but the signaling pathways 
activated by this protein remain only partially understood. Here, we describe the intracellular 
pathways triggered by PAP1 in a pancreatic acinar cell line. Taking advantage of the fact that 
PAP1 induces its own transcription, we performed ChIP assays to analyze the recruitment of 
transcriptional factors on its promoter. Our results show that PAP1 increased the 
transactivation activity of pap1 and the binding on its promoter of the nuclear factors 
C/EBP , P-CREB, P-ELK1, EGR1, STAT3 and ETS2, which are downstream targets of 
MAPK signaling. p44/42, p38 and JNK MAPKs activity increased after PAP1 treatment. In 
addition, pharmacological inhibition of these kinases markedly inhibited the induction of 
pap1 mRNA. Taken together, these results indicated that the mechanism of PAP1 action 
involves the activation of the MAPK superfamily. 
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Introduction 
Pancreatitis-associated protein 1 (PAP1) is a C-type lectin originally identified as a pancreatic 
secretory protein, not expressed under physiological conditions but strongly overexpressed 
during acute pancreatitis [1]. Its expression is actually not restricted to the pancreas and has 
been linked to a variety of diseases including inflammatory bowel disease [2], Alzheimer‟s 
disease [3] or some types of cancers such as hepatocellular carcinoma [4], pancreatic 
adenocarcinoma [5] and colorectal carcinoma [6].  
PAP1 is a 175 aminoacid long polypeptide containing one carbohydrate-binding domain 
(CBD) linked to an N-terminal sequence, part of which is cleaved during its maturation and 
secretion [7]. This protein was the first identified member of a family of proteins that 
comprises lithostatine and several isoforms of PAP sharing important sequence similarities 
[8]. Data from experimental acute pancreatitis showed that the secretory patterns of these 
proteins are coordinated, with a peak of expression in pancreatic tissue or juice 24 hours after 
the induction of acute pancreatitis by cerulein [9]. However, the levels and the expression 
pattern of these proteins are different, suggesting that these isoforms do not substitute one 
another but may have different functional properties. [10]. 
PAP1 has been described in different species under different names: it was called p23 protein 
when secreted by rat pituitary cells [11], HIP/PAP when reported in hepatocellular cancer [4] 
or Reg2 when expressed in regenerating motor neurons [12]. Also, PAP1 was shown to be 
involved in several biological functions, sometimes apparently unrelated. In pancreatic acinar 
cells, overexpression of PAP1 increases resistance to apoptosis [13, 14]. PAP1 acts as a 
growth factor promoting cell proliferation in hepatocytes [15] and motor neurons [12]. 
Moreover, PAP1 exhibits mitogen activity on Schwann cells and promotes nerve regeneration 
[16]. It also promotes intestinal epithelial cell growth [17]. A function linking cell migration 
and cell adhesion to extracellular matrix has also been proposed for PAP1 [18, 19].  
Widening the PAP1 range of functions, our group demonstrated an anti-inflammatory role for 
this protein in agreement with its strong induction during the course of inflammatory disease 
such as pancreatitis, Crohn‟s disease and ulcerative colitis. In a rat model of acute 
pancreatitis, the infusion of anti-PAP1 antibodies worsened the pancreatic inflammatory 
response [20]. In the same study, PAP1 treatment prevented TNF -induced Nuclear Factor 
kappa B (NFκB) activation in macrophages. This protective function of PAP in acute 
pancreatitis has been confirmed using antisense PAP oligonucleotides in order to block the 
expression of all three isoforms of PAP [21]. As well, Gironella et al. corroborated the anti-
inflammatory role of PAP1 in vivo in a PAP1-deficient mice model [22]. 
Although a number of studies have focused on the physiopathological significance of PAP1, 
little is known of the signal transductions triggered by PAP1. Recent data have shown that 
PAP1 inhibited the inflammatory response through a JAK/STAT3 dependent mechanism 
[23]. Nevertheless, PAP1 effects are not entirely explained by the activation of JAK/STAT3 
as it is known that signals transduction usually involves an intricate and complex network of 
interactions between several signaling pathways. The purpose of this study was to identify the 
intracellular signaling pathways induced by PAP1. Taking advantage of the fact that PAP1 
induces the expression of its own gene, we performed a Chromatin Immunoprecipitation  
assay (ChIP) to correlate transcriptional factor recruitment to the pap1 promoter with the 
signaling pathways triggered by PAP1. Our results showed that PAP1 increased the 
transactivation activity of the nuclear transcriptional factors associated with the MAPK 
superfamily. 
 
Materials and Methods 
Reagents 
All culture supplies were obtained from Invitrogen (Carlsbad, CA). Reagents for SDS-PAGE, 
blotting paper and nitrocellulose membranes were from BioRad (Hercules, CA). Antibodies 
against P-p38, P-p44/42 and P-JNK were supplied by Cell Signaling Technology (Beverly, 
MA). Antibodies against β- -CREB, P-ELK1, ATF2, EGR1, c-JUN, STAT3, 
NFκB (p65), ETS2, ATF3, SRF and RNApol II were supplied by Santa Cruz Biotechnology 
(Santa Cruz, CA). The secondary antibodies linked to horseradish peroxidase were purchased 
from Sigma (St. Louis, MO). Specific inhibitors for each MAPK families: SB203580 (p38 
MAPK inhibitor), PD98059 (p44/42 inhibitor) and JNK Inhibitor II (JNK inhibitor) were 
obtained from Calbiochem (Nottingham, UK). Recombinant human PAP1 was produced in 
the yeast Pichia Pastoris according to the recommendations of the manufacturer by Dynabio 
SA (Marseille, France). The PAP1 ELISA used to quantify PAP1 (PancrePAP) was obtained 
from Dynabio SA (Marseille, France).  
Cell culture 
Rat pancreatic acinar cells (AR42J) were grown in monolayers until 70-80% confluence in a 
Dulbecco‟s Modified Eagle‟s medium supplemented with 10% Fetal Calf Serum „Gold‟ 
(PAA Laboratories, Pasching, Austria), 2 mM L-glutamine, 100U/mL penicillin and 100 
µg/ml streptomycin (Sigma, St. Louis, MO) at 37°C in a humidified atmosphere of 95% air, 
5% CO2. Cultures were split every 3 days by trypsinization with 0.1% trypsin (Sigma, St. 
Louis, MO) in Ca2+/Mg2+-free PBS containing 0.9 mM EDTA.  
Chromatin immunoprecipitation assay and RNApol ChIP 
ChIP and RNApol ChIP procedures were performed according to Sandoval and colleagues 
[24], and Rodriguez and colleagues [25] with some modifications. AR42J cells were fixed by 
adding formaldehyde to a final concentration of 1% directly to the cell culture dish, and 
incubating for 7 minutes on a shaking platform, at room temperature. The cross linking 
reaction was stopped by adding glycine to a final concentration of 0.125 M, and cells were 
then washed twice with ice-cold PBS, scrapped and recovered by centrifugation at 3000×g for 
5 min. The pelleted cells were resuspended in 6 ml of cell lysis buffer (HEPES 5mM, pH 8, 
KCl 85 mM, NP40 0.5%) supplemented with protease inhibitor cocktail (Sigma), incubated 
on ice for 15 min and centrifuged at 1000×g for 5 min. The nuclei pellet was resuspended in 
1ml of nuclei lysis buffer (Tris-HCl 50 mM, pH 8.1, EDTA 10 mM, SDS 1%) and stored at -
80 ºC until use.  
Cross-linked chromatin was sonicated on ice during 8 pulses of 10 s each, with a 37% 
amplitude on a Vibra-Cell VCX-500 sonicator (Sonics and Materials, Newtown, CT) to 
obtain chromatin fragments of 300-500 bp. This target size of chromatin fragments was 
confirmed by agarose gel electrophoresis. The sonicated chromatin was centrifuged at 
14,000×g for 10 min, and the supernatants were diluted 10-fold with dilution buffer (NaCl 
165 Mm, SDS 0.01%, Triton X-100 1.1%, EDTA 1.2 mM, Tris-HCl 16.7 mM, pH 8.0) 
supplemented with protease inhibitor cocktail (Sigma, St. Louis, MO). Aliquots from the 
diluted supernatants (equivalent to 50 μg DNA) were taken and incubated for 2 h at 4ºC with 
Dynabeads-protein G (Invitrogen, Carlsbad, CA) previously washed with PBS/BSA (5mg/ml) 
and saturated with tRNA from E. coli and 2 μg of the corresponding antibody on a rotating 
-CREB, P-ELK1, ATF2, EGR1, c-JUN, STAT3, NFκB (p65), ETS2, 
ATF3 and SRF for ChIP assay, or RNApol II for RNApol ChIP). The chromatin 
fragment/antibody/protein G-Dynabead immunocomplexes, were recovered applying a 
magnetic field, by placing the sample containing tubes in the appropriate magnet (Invitrogen, 
Carlsbad, CA). Immunocomplexes were washed twice with ice-cold low-salt buffer (HEPES 
50 mM, pH 8.0, NaCl 140 mM, Triton X-100 1%, Sodium Desoxycholate 0.1% ,EDTA 
1mM), twice with ice-cold high-salt buffer (HEPES 50 mM, pH 8.0, NaCl 500 mM, Triton X-
100 1%, Sodium Deoxycholate 0.1% ,EDTA 1mM), twice with ice-cold LiCl buffer (Tris-
HCl 10mM, LiCl 250 mM, NP-40 0.5%, Sodium Deoxycholate 0.5%, EDTA 1mM) and 
finally once with TE buffer. During each washing step, the Dynabead suspensions were kept 
under rotation for 4 min at 4 ºC, and recovered with the magnet. After the elimination of any 
remaining TE buffer from the last wash, the immunoselected chromatin was eluted from the 
Dynabead-protein G in two consecutive steps, by adding 50 µl of elution buffer (Tris-HCl 50 
mM, EDTA 10 mM, SDS 1%), vortexing and incubating for 10 min at 65ºC. The resulting 
100 μl fraction (IP fraction) was incubated at 65 ºC overnight to reverse formaldehyde 
crosslinks, in the presence of proteinase K (0.4 mg/ml). An aliquot of the cross-linked and 
diluted chromatin was treated in parallel as above, but in the absence of antibody (NoAb 
fraction) and the first supernatant, resulting from putting the sample on the magnet prior to the 
washing steps, was saved as the Input fraction. The DNA from all these samples (IP, NoAb 
and Input) was purified with a PCR purification kit (Qiagen, Valencia, CA) and used for PCR 
analysis of the target gen.  
PCR analysis of immunoprecipitated chromatin.  
Input, IP and (NoAb) fractions were analysed by PCR with the appropriate primer pairs to 
amplify products of 200 to 300 bp in length, corresponding to either the promoter or the 
coding regions of the target gene. For the analysis, 1:500 dilutions of the Input and 1:30 of the 
IP and NoAb fractions were used. Primers were designed to amplify rat pap1 promoter and rat 
pap1 coding region. PCR fragments were size-fractionated by 2% agarose gel electrophoresis, 
stained with ethidium bromide and photographed with FLA3000 electronic autoradiography 
system (Fujifilm, Japan). Analysis of constitutive expressed β-actin gene was used as a 
positive control and analysis of an intergenic region was used as a negative control. Sequence 
primers are showed in Table 1. 
RNA isolation and RT-PCR 
Analysis of the expression of pap1 was conducted using a semiquantitative RT-PCR method. 
Total RNA from cells was extracted using the Trizol reagent (Invitrogen, Carlsbad, CA). One 
µg total RNA was used for amplification using the Promega AccessQuick RT-PCR System 
(Promega, Madison, WI) according to the manufacturer‟s instructions. The following primers 
were used: rat pap1 and rat gapdh as internal control for stable expression (housekeeping 
gene). Respective sequence primers are in Table 1. Fragments were amplified using 25-30 
cycles of PCR, each cycle consisting of 15 s at 94°C, 30 s at 55°C, and 1 min at 72°C. The 
resulting RT-PCR products were electrophoresed on 2% agarose gels with DNA markers, 
stained with ethidium bromide, and visualized under UV light.  
Real-time quantitative PCR 
Total RNA was isolated from AR42J cells exposed to PAP1 for 20 min and from non-treated 
control cells, using the Trizol reagent (Invitrogen, Carlsbad, CA). The RNA was quantified by 
measurement of the absorbance at 260 and 280 nm using a NanoDrop ND-1000 
spectrophotometer (NanoDrop Technologies, USA). Reverse transcriptase real-time 
quantitative PCR was performed using an ABI Prism 7000 thermal cycler (Applied 
Biosystems, Foster City, CA). RT-PCR mixtures contained 0.5 μg of total RNA and 200 nM 
each of the forward and reverse primers. Primers were designed to amplify rat pap1 and rat 
gapdh as a housekeeping gene. Respective sequence primers are showed in Table 1. Reaction 
mixtures also contained HotStart Taq DNA polymerase, DNA double-stranded specific 
SYBR Green I dye, OmniScript and SensiScript reverse transcriptases, ROX passive dye, and 
nucleotides (Quantitect SYBR Green RT-PCR kit; Qiagen, Valencia, CA). Amplification was 
achieved following an initial incubation at 50 °C for 30 min, followed by denaturation at 95 
°C for 15 min, and then 40 cycles of 94 °C for 15 s, 60 °C for 30 s, and 72 °C for 30 s. At the 
end of the 40 cycles, samples were subjected to melting analyses to confirm the specificity of 
PCR products. The fold induction of pap1 mRNA was determined by the ΔCt relative 
quantification method (Applied Biosystems, Foster City, CA). The amount of mRNA in each 
sample was normalized to the level of gapdh in cognate samples.  
Chloramphenicol Acetyltransferase gene reporter assay and cell transfection 
The rat pap1 gene promoter fragment including nucleotides -1253 to +10 was inserted 
upstream of the Chloramphenicol Acetyltransferase (CAT) gene in the pCAT-Basic vector 
(Promega, Madison, WI) as previously reported [26]. AR42J cells (3 x 10
5
 per plate) were 
plated in 50-mm diameter culture plates 24 hours before transfection. For each plate, 1 µg of 
the reporter vector (-1253 to +10-PAP1-CAT) and 1 µg of pCMV/ -gal were added to 6 µl of 
FuGENE 6 according to the instructions of the supplier (Roche, Palo Alto, CA). The mixture 
was added to Dulbecco‟s modified Eagle‟s medium containing 3 ml of 10% (w/v) FCS. After 
24 hours in culture, cells were treated with 500 ng of PAP1 alone or in combination with 
SB203580 (10 µM), PD98059 (100 µM) or the JNK Inhibitor II (100 µM) for an additional 
24 hours-period. Cell extracts were prepared using the reporter lysis buffer (Promega, 
Madison, WI). CAT activity was determined using the phase-extraction procedure [27] and 
the -galactosidase assay was performed essentially as described previously [26]. CAT 
activity was normalized to the -galactosidase activity. CAT and -galactosidase activities 
were always within linear range of the assay. 
SDS-PAGE and Western blot 
Cells were lysed using the Nuclear Extract Kit (Active Motif, Carlsbad, CA) under conditions 
for preparation of cytoplasmatic and nuclear extracts. SDS-PAGE was performed on 10% 
acrylamide gels. Proteins were electrotransferred to nitrocellulose membranes and probed 
with primary antibody (anti-P-p38 1/1000, anti-P-p44/42 1/1000, anti-P-JNK 1/1000; Anti-β-
actin 1/1000). The membranes were incubated with the corresponding peroxidase-conjugated 
secondary Ab, washed, and then incubated with ECL reagents from Bio-Rad (Hercules, CA) 
before exposure to high performance chemiluminescence films. Gels were calibrated using 
Bio-Rad standard proteins (Hercules, CA) with markers covering a 7-240 kDa range.  
Bioinformatic analysis of pap1 promoter region 
pap1 promoter sequence (1000 bp) was analysed using the transcription factor binding sites 
(TFBS) analysis tool MatInspector (http://www.genomatix.de/) [28].  
Statistical analysis 
Data were expressed as mean ± SEM. Means of values from different groups were compared 
using a one-way analysis of variance. Tukey‟s multiple comparison test was performed for 
evaluation the significance of differences between groups. Differences were assumed to be 
significant when p<0.05. 
Densitometric analysis 
ImageJ 1.32 software (obtained from the http://rsbweb.nih.gov/ij/download.html) was used to 
quantify the intensities of the bands obtained in PCR experiments. 
Results 
Induction of pap1 gene expression in response to PAP1  
We confirmed our previous results showing the positive feedback induction of PAP1 in 
AR42J pancreatic acinar cells. AR42J cells displayed a time-dependent induction of pap1 
gene expression after adding PAP1 to the culture media. Kinetic analysis of the induction 
revealed that the levels of pap1 mRNA increased 30 min after addition of PAP1 at 500ng/ml 
(Figure 1A). This dose has been previously reported to be effective in inducing PAP1 itself 
[23]. Specificity of PAP1 induced response was verified by incubating the protein with 1µM 
of rabbit anti-PAP1 neutralizing antibody [20] for 30 minutes. Then, AR42J cells were 
stimulated with this mixture for 40 minutes. Figure 1B shows the effective neutralizing ability 
of anti-PAP1 antibody on PAP1 induction. These results allowed us to use the pap1 gene 
promoter as a strategy to study the signaling pathways activated by PAP1 using ChIP and 
RNApol ChIP assays. 
Identification of transcription factors bound to the pap1 gene promoter in vivo  
To verify the binding of regulatory factors to the pap1 promoter in response to PAP1, we 
carried out a ChIP assay in growing AR42J cells. After cross-linking and 
immunoprecipitation, enrichment of the human pap1 promoter was monitored by PCR 
amplification using specific primers for the promoter region. In order to verify the results 
obtained, the same samples employed for the ChIP assay were used for the RNA polymerase 
ChIP assay, as previously described. The α-RNA polymerase antibody precipitated both 
promoter and coding chromatin fragments, thus confirming that the pap1 gene is expressed in 
AR42J cells. An augmented transcription was observed 20 min after PAP1 addition to the cell 
culture medium (Figure. 2). In that basis, we established an incubation time of 20 min to test 
the binding of nuclear regulatory factors to the pap1 promoter region. In vivo binding of 
factors to pap1 promoter -CREB, P-ELK1, 
ATF2, EGR1, c-JUN, STAT3, NFκB (p65), ETS2, ATF3 and SRF. Figure 3 depicts the 
presence of downstream targets of PAP1. EGR1 and STAT3 bound to the promoter region of 
pap1 gene in cells without PAP1 treatment. After stimulation with PAP1, the binding of 
C/EB -CREB, P-ELK1, EGR1, STAT3 and ETS2 was dramatically increased, while that 
of ATF2, c-JUN, NFκB (p65), ATF3 and SRF remained unchanged. 
PAP1 signal transduction involved MAPK signaling pathway 
Next, we investigated whether PAP1 directly affect MAPK signaling. We used Western blot 
and specific antibodies against the active (phosphorylated) forms of the kinases. As 
summarized in Figure 4, AR42J cells presented basal levels of phosphorylation of the three 
members of the MAPK superfamily: p44/42, p38 and JNK. However, 30 min after PAP1 
treatment, an augmented activation of the p44/42, p38 and JNK protein kinases was observed, 
suggesting that PAP1 signal transduction involves the MAPK superfamily. 
Effect of MAPKs specific inhibitors on PAP1-mediated induction of pap1 mRNAGiven 
the fact that PAP1 enhanced the phosphorylation of MAPK family members, we examined 
the effect of MAPK specific inhibitors on PAP1-mediated induction of pap1 mRNA. 
Pancreatic acinar cells were treated for 20 min with vehicle, PAP1 (500ng/ml) or pre-treated 
with different MAPK specific inhibitors: SB203580 (p38 MAPK inhibitor; 100µM), 
PD98059 (p44/42 inhibitor; 100 µM), and JNK Inhibitor II (100 µM) for 30 min and then 
stimulated with PAP1. As shown in Figure 5, the pharmacological inhibition of the three main 
MAPK family members markedly inhibited the activation of pap1 mRNA, thus indicating that 
activation of the MAPK superfamily is essential for pap1 mRNA synthesis in response to 
PAP1. In order to verify the effect of MAPK inhibition on the activation of the pap1 
promoter, an additional experiment was carried out using a gene reporter assay. Figure 6 
shows that all inhibitors resulted in a blockage of the CAT activity induced by PAP1. 
Discussion 
A plethora of functional roles have been attributed to the stress-induced secretory protein 
PAP1. This protein has been reported to be mitogenic, anti-apoptotic or anti-inflammatory, to 
regulate cellular adhesion, promote bacterial aggregation or increase resistance to anti-tumoral 
agents, the nature of these functions depending on the cell type used as model and the 
environment. 
Since different investigators have attributed diverse physiological roles to PAP1, little is 
known about the downstream signaling pathways activated by PAP1. To date, it was shown 
that in cultured motor neurons, PAP1 signals for survival through the phosphoinositol-3-
kinase (PI3 kinase)/AKT kinase pathway [12]. In hepatocytes, PAP1 stimulates PKA-
dependent phosphorylation of the pro-apoptotic Bad protein, suggesting that PAP1 may 
compete with cAMP to stimulate PKA activity [15]. Moreover, recent data have shown an anti-
inflammatory role for PAP1 through the inhibition of NFκB signaling induced by TNFα in 
pancreatic acinar cells [23]. This inhibition takes place as a result of JAK/STAT3 activation 
suggesting the existence of a crosstalk between both signaling pathways.  
Despite this well documented data, it can barely account for all PAP1 functions. In an effort 
to complete the picture, we used a pancreatic acinar cell line AR42J known to respond to 
PAP1. In a previous work on this cell line, we used immunopurified PAP1 from rat pancreatic 
juice to describe a positive feedback mechanism of PAP1. Here we show the same results 
using human PAP1 produced in Pichia Pastoris, which is not a surprise given the important 
sequence similarities between the two homologs. Analysis of the kinetics of PAP1 induction 
revealed that pap1 mRNA expression analyzed by RT-PCR in response to PAP1 itself was 
time–dependent (Figure 1A) and already increased 30 min after the treatment. The specificity 
of PAP1 induced response was verified using a neutralizing anti-PAP1 antibody (Figure 1B). 
These results allowed us to use the ChIP assay on the pap1 gene promoter to study the 
signaling pathways activated by PAP1. We, therefore, tested by RNApol ChIP assay the 
recruitment of the RNA α-polymerase to pap1 promoter. As shown in Figure 2, an enhanced 
binding of the RNApol II transcriptional complex is observed 20 min after PAP1 addition to 
the cell culture medium.  
Several potential transcription factor binding sites are present on the pap1 promoter. Analysis 
of the 1 kb promoter sequence revealed potential binding sites of some important transcription 
factors, including C/EBP, P-CREB, ATF2, STAT3, ETS2 and SRF. In addition to these, we 
also evaluated the binding of the nuclear factors P-ELK1, EGR1, c-JUN, NFκB and ATF3 to 
study their effects on pap1 promoter occupation. As shown on Figure 3, EGR1 and STAT3 
are bound to pap1 promoter in the absence of PAP1 treatment indicating that pap1 may be 
considered as a “potentially active” gene prepared to respond promptly to an appropriated 
cellular stimulus. After stimulation with PAP1, we could obtain significant amplification of 
the pap1 promoter region from DNA co-immunoprecipitated using the -CREB, P-
ELK1, EGR1, STAT3 and ETS2 antibodies, indicating that in these conditions, these 
transcription factors are bound to the binding site of pap1 promoter gene in the cells. In a 
previous study, we already reported the PAP1 positive feedback through a JAK/STAT3 
mechanism [23]. Therefore, the binding of STAT3 to the PAP1 promoter would be consistent 
with the STAT3-dependent role of PAP1.  
Regarding NFκB, we did not find this nuclear factor bound to the PAP1 promoter. This result 
is in keeping with previous studies showing no activation of NFκB in pancreatic acinar cells 
or macrophages in response to PAP1 [23, 2]. However, different results have been found with 
other PAP isoforms. Using a rat macrophage cell line, Viterbo et al. reported that PAP2, the 
most expressed PAP isoform during acute pancreatitis, up-regulated the expression of pro-
inflammatory cytokines IL1, IL6 and TNFα [29]. These differences seem to be related with 
the different functional properties shown by the different members of the PAP superfamily 
[10]. 
The activation of nuclear factors -CREB, P-ELK1, EGR1 and ETS2 observed in 
response to PAP1 served as a specific readout for MAPK superfamily activation. 
Nevertheless, other signaling cascades such as the PI3 kinase/AKT and Ca
2+
-specific signals 
activated by growth factors or cellular stress are known to converge on some of these factors, 
controlling their activity.  
Then, we further delineated the possible influence of PAP1 on the activation of MAPK 
signaling pathway. A wide variety of extracellular stimuli induce sequential phosphorylation 
and activation of the MAPK pathway. This superfamily of proteins consists of three main 
protein kinase families: the extracellular signal-regulated protein kinases (ERK or p44/42), 
the c-Jun N-terminal kinases (JNK) and the p38 family of kinases. Each molecule is activated 
by distinct pathways and transmits signals either independently or in coordination [30, 31]. 
The MAPK pathway is involved in diverse cellular functions including cell proliferation, cell 
differentiation and apoptosis as well as inflammation. Thus, it is conceivable that PAP1 
triggers the MAPK signaling pathway. In this line, Lieu et al. reported changes in p44/42 
activation in PAP1 knockout mice during liver regeneration, suggesting that this MAPK could 
be involved in the regenerative effects of PAP1 [32].  
Western Blot analysis of MAPK indicated that AR42J cells presented with a basal level of 
phosphorylation of p44/42, p38 and JNK (Figure 4). However, PAP1 treatment enhanced the 
phosphorylation of all three MAPKs, suggesting that some of the effects of PAP1 could be 
mediated by activation of MAPK signaling and thus downstream transcription events. This 
possibility was evaluated by using specific inhibitors of these three major families of MAPKs 
and measuring the induction of pap1 mRNA as well as the activation of pap1 gene promoter 
in a gene reporter assay. Results indicated that the addition of p44/42, p38 and JNK 
pharmacological inhibitors completely blocked the activation of pap1 promoter as well as the 
induction of pap1 mRNA in response to PAP1 (Figures 5 and 6). It was therefore concluded 
that these signaling events are necessary to pap1 gene regulation. 
Most experimental evidences obtained so far demonstrate that MAPK signaling cascades are 
involved in the pathogenesis of acute pancreatitis [33]. An early activation of all three MAPK 
in the pancreas within minutes was indeed observed in experiments involving various models of 
experimental acute pancreatitis [34-36]. This is of interest given the fact that our results 
indicate that PAP1 induces itself in a positive feedback mechanism mediated by MAPKs 
activation. In these conditions, it is not surprising to find high amounts of this protein during 
this acute inflammatory disease.  
Finally, some reports indicate that MAPK cascades can also influence other signaling 
pathways. It is known that p44/42 participate in STAT3 serine 727 phosphorylation in vivo in 
growth factor-stimulated cells and in vitro as well [37] suggesting a possible dynamic 
interplay between both MAPK and JAK/STAT3 pathway upon activation by PAP1.  
In summary, the present study demonstrates that part of the physiological effects of PAP1, 
including its self-induction, is strongly dependent on the activation of MAPK signaling 
pathway (figure 7). These results make a contribution to the in-depth knowledge of the 
mechanisms involved in PAP1 physiological functions.  
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Table 1: Primers used for RT-PCR and real time PCR 
 
Name                    Primer 
rat pap1 (promoter)             Forward: 5´-ATGCCACCATTTTTTCCTTGTG-3´ 
                                            Reverse: 5´-GAT GGGAAGCACTTGGCATT-3´     
rat pap1 (coding region)      Forward: 5´-CAAAGGCTCCC AGGCATATG-3´  
                                             Reverse: 5´- GGCCAGCTATGTGAGGAACAA-3´       
rat pap1 (real time)              Forward: 5‟-ACTCCATGACCCCACTCTTG -3‟  
                                             Reverse: 5‟-TGACAAGCTGCCACAGAATC -3‟ 
rat β-actin (coding region)   Forward: 5´-AGAGCAAGAGAGGCATCCTG-3‟ 
             Reverse: 5‟-GGGTCATCTTTTCACGGTTGG-3‟ 
rat gapdh (real time)            Forward: 5‟-GTGTGTCTTTCCGCTGTTTTC -3‟  
                                             Reverse: 5‟-TGTGCTGTGCTTATGGTCTCA 3‟ 
rat pap1  (RT-PCR)              Forward: 5‟-TGACAAGCTGCCACAGAATC-3‟  
                                             Reverse: 5‟-GCTCCTACTGCTATGCCCTG-3‟ 
rat gapdh   (RT-PCR)           Forward: 5‟-ATGGGAAGCTGGTCATCAAC-3‟ 
                                             Reverse: 5‟-CCACAGTCTTCTGAGTGGCA-3‟ 
rat intergenic             Forward: 5‟-TGCCGGTTATCACTCTCTCATGC-3‟ 
             Reverse: 5‟-GGTCTTGGTTCAGTCTTCACATGC-3‟ 
 
 
                               
Figure legends 
Figure 1. Time course of pap1 mRNA expression in response to PAP1. AR42J cells were 
stimulated with 500ng PAP1/mL culture medium at different time-points (A) or with a 
mixture of PAP1 plus a blocking anti-PAP1 antibody for 40 min (B). Total RNA was 
extracted and subjected to RT-PCR using specific primers for pap1 and gapdh (internal 
control). Products were analyzed by 2% agarose ethidium bromide gel. Results are shown for 
one of three representative experiments. 
Figure 2. RNApol ChIP analysis of the rat pap1 transcription at different times of PAP1 
treatment. The cross-linked chromatin samples were immunoprecipitated with an anti-RNA 
polymerase II antibody and the immunoprecipitate were analyzed by PCR using primers 
specific for the pap1 coding region. For each time-point, a sample of total chromatin (Input) 
was included in the PCR. The presence of RNA polymerase in these regions is taken as a 
measure of actual transcription. Constitutive expressed β-actin gene was used as a positive 
control and an intergenic region was used as a negative control. No Ab, no antibody. 
Figure 3. ChIP analysis of pap1 promoter occupation during PAP1-treated AR42J cells. 
ChIP analysis was performed to monitor the binding of nuclear factors within the PAP1 
promoter. In vivo binding of factors to pap1 gene 20 min after PAP1 treatment was monitored 
-CREB, P-ELK1, ATF2, EGR1, c-JUN, STAT3, NFκB 
(p65), ETS2, ATF3 and SRF. The immunoprecipitated samples were analyzed by PCR using 
primers of the pap1 promoter region. The normalized integrated density of the 
immunoprecipitated samples bands was included as a quantification of the relative intensity of 
the transcriptional binding. Results are shown for one of three representative experiments. 
Figure 4. Effect of PAP1 on MAPKs activity. Phosphorylation levels in response to PAP1 
of the three main members of the MAPK superfamily were assessed by Western blot. AR42J 
cells were stimulated with or without 500ng/ml PAP1 for 30 min and cell lysates were 
subjected to immunoblotting using anti-P-p44/42 (A), anti-P-p38 (B) and anti-P-JNK (C) 
antibodies. The presence of PAP1 enhanced the expression of phosphorylated, active forms of 
the three MAPKs. The same membranes were re-blotted for anti-β-actin to check loads were 
similar. Immunoblots shown are representative for one of three independent experiments. 
Figure 5. Effect of MAPK specific inhibitors on PAP1-mediated induction of pap1 
mRNA. AR42J cells were treated for 20 min with vehicle, PAP1 (500 ng/ml) or pre-treated 
with different MAPK specific inhibitors: p44/42 inhibitor (SB203580; 100 µM), p38 inhibitor 
(PD98059; 100 µM), and JNK inhibitor (JNK Inhibitor II; 100 µM) for 30 min before 
stimulation with PAP1. pap1 mRNA induction levels were quantified by real-time PCR and 
normalized to gapdh mRNA expression. p38, p44/42 and JNK MAPKs inhibitors decreased 
pap1 mRNA induction. Results are expressed as mean values ± S.E.M. 
*
p<0.05 vs C, 
+
p<0.05 
vs P. C, control. P, PAP1. Results are shown for one of three representative experiments. 
Figure 6. Transcription activation of the pap1 promoter by PAP1 is inhibited by MAPK 
inhibitors SB203580, PD98059 and the JNK Inhibitor II. AR42J cells were transiently 
transfected with the -1253 to +10-PAP1-CAT construct together with pCMV/β-gal vector 
used as an internal control for the transfections. After transfection, the cells were incubated 
for 24 h and then incubated with 500 ng of PAP1 alone or in combination with p44/42 
inhibitor (SB203580; 100 µM), p38 inhibitor (PD98059; 100 µM), and JNK inhibitor (JNK 
Inhibitor II; 100 µM) by an additional 24 hours-period. Cells were then harvested, lysed and 
assayed for both CAT and β-galactosidase activities. Results are expressed as mean values ± 
S.E.M. 
*
p<0.05 vs C, 
+
p<0.05 vs P. C, control. P, PAP1. Results are shown for one of three 
independent experiments.  
Figure 7. Schematic diagram of MAPKs signal transduction pathway induced by PAP1. 
In AR42J cells, we provide evidence for activation of three MAPKs by PAP1: p38, p44/42 
and JNK MAPKs are induced as consequence of the interaction of PAP1 with its receptor and 
subsequently phosphorylated. Several nuclear factors related to the MAPK family eventually 
bind the promoter region of PAP1. 
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